Moderna to raise $2B in convertible notes after cancer vaccine rally
What's the deal? ModernaDealroom has a profile for this one. Try Dealroom → will raise $2 billion by selling convertible senior notes due 2032, the Cambridge, Massachusetts-based biotech said Thursday. Proceeds are earmarked for its cancer vaccine business and debt repayment.
The offering includes an option for purchasers to buy up to $300 million more in notes. Moderna stock fell 5% in premarket trading in New York after the announcement.
Why now? The raise follows a 177% rally in Moderna's stock on August 19, which added $44.5 billion to its market capitalisation in a single session. The surge came after the company reported encouraging data from a late-stage study of a personalised mRNA cancer vaccine co-developed with Merck & CoDealroom has a profile for this one. Try Dealroom →.
Bringing a convertible offering to market after a sharp share-price jump is common practice, securing favourable borrowing terms when investor demand is strong, according to BloombergDealroom has a profile for this one. Try Dealroom →.
Why it matters: With the stock near a multi-year peak, Moderna can negotiate a higher conversion price on the notes. That means fewer new shares enter circulation if the notes convert, protecting existing stockholders from dilution, according to Bloomberg.
The signal: At $2 billion, the deal ranks in the top 1% of post-IPO convertible rounds in US health over the trailing 48 months, out of 199 comparable deals. It marks a rare moment when a biotech's clinical momentum and market timing align to fund its next bet on cheap capital.
Image credit: Generated with Gemini
